Pharmacist Qualifying Examination Part I (MCQ): Applied Biomedical and Therapeutic Reasoning
The Part I MCQ examination assesses whether you can apply biomedical, pharmaceutical, and therapeutic knowledge to short case vignettes. Expect items that ask for the best next step, the mechanism behind an adverse effect, a monitoring parameter, or a legal requirement. Questions reflect Canadian practice, so Canadian guidelines, generic/brand naming, and federal/provincial rules matter.
Core rules and concepts
- Mechanism first: link drug class to receptor or enzyme target, then predict effect and adverse effect. For example, ACE inhibitors reduce angiotensin II and aldosterone, raising bradykinin and potassium.
- Pharmacokinetics: use half-life to estimate steady state (about 4–5 half-lives), volume of distribution for loading dose, and renal function for dose adjustment.
- Therapeutics: know first-line options and key contraindications. In hypertension, an ACE inhibitor/ARB, dihydropyridine calcium channel blocker, or thiazide is commonly first-line; avoid ACE inhibitor/ARB in pregnancy.
- Practice/legal: prescription essentials, controlled drug rules, consent, confidentiality, and documentation.
Worked example
A 68-year-old with type 2 diabetes has an eGFR of 28 mL/min/1.73 m² and takes metformin 1,000 mg twice daily. What is the best action? Reasoning: Metformin is contraindicated when eGFR is below 30 because of lactic acidosis risk. The correct action is to discontinue metformin and consider an alternative glucose-lowering agent. Do not merely reduce the dose; at eGFR 30–45, initiation is avoided and continuation requires reassessment, but below 30 it should be stopped. The eGFR number, not the glucose value, drives the answer.
Traps that cost marks
- Choosing a US guideline or unfamiliar brand name over Canadian practice.
- Confusing contraindication with precaution, as with metformin across eGFR thresholds.
- Forgetting monitoring: potassium and creatinine with ACE inhibitor/ARB, INR with warfarin.
- Selecting “refer to emergency” when the scenario calls for pharmacist management or routine follow-up.